ClinicalTrials.gg
CompletedNCT05002946Updated May 3, 2022

Pharmacokinetics of SP-104

A Phase 1 interventional study of SP-104 and Naltrexone Hydrochloride 50Mg Oral Tablet in Healthy, sponsored by Scilex Pharmaceuticals, Inc.. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Scilex Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This open-label, 3-period, 3-treatment, randomized study will characterize the pharmacokinetics and safety and tolerability of SP-104 under fasting and fed conditions as compared to the pharmacokinetics of Naltrexone Hydrochloride Tablets, USP, 50 mg in healthy adult subjects.

Read the detailed description

The study will characterize the single-dose pharmacokinetics of naltrexone and metabolite (6 Beta-naltrexol) following administration of SP-104 compared to Naltrexone Hydrochloride Tablets, USP, 50 mg in healthy adult subjects under fasting conditions. The study will also characterize the effect of food intake on the pharmacokinetics of SP-104 in healthy adult subjects. Additionally, the safety and tolerability of single doses of SP-104 under fed and fasting conditions will be characterized.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Scilex Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide , can understand and comply with the requirements of the study, and are able to communicate with the investigator.
  • male and female adult subjects between 18 and 65 years.
  • (BMI) of 18-32 kg/m2.
  • Medically healthy
  • Agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or to the use of an effective method of from screening through until at least 30 days after the last study dose.
  • Able to swallow capsules and tablets.

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of disease, including cardiovascular, GI, renal, hepatic, pulmonary, endocrine, hematologic, vascular, immunologic, metabolic, or collagen disease.
  • History of drug or alcohol abuse or dependence based on the criteria as reported by the subject or known to the Investigator.
  • Subjects currently dependent on opioids, including those currently maintained on opiate agonists or partial agonists.
  • Subjects in acute opioid withdrawal.
  • Use of any other drug within 30 days or 6 half-lives, whichever is longer, prior to Day 1 of Period 1.
  • Use of prescription medications including opioids, or natural food supplements, alcohol, grapefruit juice, or caffeine within study-specified timeframes.
  • Positive urine drug screen for alcohol and drugs of abuse.
  • History of allergic or adverse response to naltrexone.
  • Serology positive for surface antigen, antibodies, or antibodies.
  • Subjects with current or past SARS-CoV-2 infection.
  • Are smokers, 'and any use of other types of tobacco or nicotine products within six months prior to Day 1 of Period 1.
  • Have donated plasma within 7 days prior Day 1 of Period 1.
  • Have donated or lost whole blood prior to administration of the study medication as follows: 50 to 499 mL of whole blood within 30 days, or more than 499 mL of whole within the last 56 days prior to drug administration.
  • Have had a serious illness in the 4 weeks preceding the Screening Visit that resulted in missed work or hospitalization (note: subjects missing work due to non-serious illness is not excluded).
  • Acute illness, especially any infection, within 4 weeks prior to Day 1 of Period 1.
  • Subjects with \<90 mL/min at Screening .
  • Subjects with any elevation of liver function tests .
  • \<12.0 g/dL for males or \<10.0 g/dL for females .
  • Subjects with a CK value of greater than the that is not explainable by exercise and that does not come back to reference range upon retest.
  • Any history of cancer or any active except for successfully treated basal cell carcinoma or squamous cell carcinoma.
  • Subjects with reported history of, or current treatment for, GI disease such as diverticulitis, diverticulosis, irritable bowel diseases, ulcer, inflammatory bowel disease or history of conditions, such as abdominal gunshot wounds.
  • Are an employee, family member, Sponsor, or student of the Investigator or of the clinical site.
  • Clinical judgment by the investigator that the subject should not participate in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    A: SP-104 Fasting

    Oral administration of SP-104 under fasting conditions

    Drug: SP-104

  • Experimental
    B: SP-104 Under Fed Conditions

    Oral administration of SP-104 under fed conditions

    Drug: SP-104

  • Active comparator
    Naltrexone Hydrochloride Tablets Fasting

    Oral administration of Naltrexone Hydrochloride Tablets, 50 mg USP under fasting

    Drug: Naltrexone Hydrochloride 50Mg Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Concentration of SP-104

    Observed plasma concentrations of naltrexone and metabolite 6β-naltrexol ng/mL

    Time frame: 72 hours

  2. Time to maximum concentration of naltrexone and metabolite 6β-naltrexol

    Time to maximum plasma concentration of naltrexone and metabolite 6β-naltrexol in minutes

    Time frame: 72 hours

07

Study locations

1 site
  • Christchurch Clinical Studies Trust (NZCR)
    Christchurch, 8011, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Apr 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2021
First posted
Aug 12, 2021
StartActual
Jan 11, 2022
Primary completionActual
Apr 24, 2022
CompletionActual
Apr 24, 2022
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05002946
Lead sponsor
Scilex Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Jan 11, 2022
Primary completion
Apr 24, 2022
Completion
Apr 24, 2022
Last update
May 3, 2022

Study contacts

Dmitri Lissin, MD
study director · Scilex Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion